---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-001923"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:29:15.664642+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics expands levosimendan license to worldwide rights from Orion

## Summary
- Amendment expands Tenax's exclusive global rights to levosimendan for PH-HFpEF from North America to worldwide.
- Royalty rates improved to high single-digit to low-teen percentages; maximum cost of goods reduced.
- Milestone payments: $10M on US FDA approval (increased), $5M on Japan approval; up to $45M for commercial milestones.
- Tenax retains right of first negotiation for all indications except neurological, which are excluded.

## SEC filing metadata
- accession: 0001654954-24-001923
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424001923/0001654954-24-001923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424001923/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-001923
- JSON: https://secwatch.observer/filing/0001654954-24-001923.json
- Plain text: https://secwatch.observer/filing/0001654954-24-001923.txt

## Key facts
- Material Agreements
  TENAX THERAPEUTICS, INC. amended Amendment with Orion Corporation (effective 2024-02-19).
  - Action: amendment
  - Agreement: license
  - Counterparty: Orion Corporation
  - Effective: 2024-02-19
  source text: On February 19, 2024, Tenax Therapeutics, Inc. (the “Company”) and Orion Corporation (“Orion”) entered into an amendment (the “Amendment”) to that certain License Agreement between the Company and Orion dated as of September 20, 2013, as previously amended on October 9, 2020 and January 25, 2022 (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424001923/0001654954-24-001923-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.